key: cord-0931589-t795j6kd
authors: Qi, Hai
title: A commentary of Messenger RNA vaccines in MIT Technology Review 2021
date: 2021-11-30
journal: Fundamental Research
DOI: 10.1016/j.fmre.2021.11.017
sha: ae492f78127a84d8cb4b111dbbd0e74d325ebe60
doc_id: 931589
cord_uid: t795j6kd

One hundred years after the 1918 influenza pandemic, the world has seen another major outbreak on a global scale. This one is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), an enveloped positive-sense single-stranded RNA virus. According to the World Health Organization, as of June 17, 2021, there have been 176,693,988 confirmed cases of human coronavirus disease 2019 (COVID-19), resulting in 3,830,304 deaths. Vaccines are the most effective way to prevent viral infection. During this pandemic, the speed at which the vaccine progressed from research and development to application was unprecedented. As of June 15, 2021, a total of 2,377,780,590 doses of various vaccines against SARS-CoV-2 have been administered worldwide. These vaccines included the messenger RNA (mRNA) vaccine, which became famous upon their debut application in the real world and was listed as one of the ‘10 Breakthrough Technologies of 2021’ by MIT Technology Review. ① ① Original source in Chinese: H. Qi, mRNA, Bulletin of National Natural Science Foundation of China. 35 (3) (2021) 402-403.

○ mRNA refers to messenger RNA, a single-stranded RNA that contains the genetic information to encode proteins. In cells, amino acids are arranged in a specific order to make up proteins under the guidance of the mRNA, which acts as an 'instructor' for the 'protein factory' in the cell. Many people have proposed introducing mRNAs synthesized in vitro into cells to guide the work of the 'protein factory'. The first study to prove that the mRNA transcribed in vitro could be used to guide protein synthesis in vivo was published in 1990, in which Wolff et al. injected mRNA encoding -galactosidase into mouse skeletal muscle and subsequently detected -galactosidase activity. Two years later, Jirikowski et al. expressed functionally active vasopressin using exogenous mRNA in rats. Although these early studies demonstrated the feasibility of mRNA as a potential treatment vector, the shortcomings of the practical applications of mRNA are obvious. Messenger RNA is itself not stable enough and prone to degradation in vivo , making targeted cell delivery challenging. Moreover, mRNA may also elicit strong immune and inflammatory responses. Therefore, for many years, mRNA was not considered a key area of focus in the development of nucleic acid therapeutics.

Technological advances in the past decade have significantly reduced the immunogenicity of mRNA and improved its safety through artificial modifications of the mRNA. The lipid nanoparticle-encapsulated mRNA delivery technology has also significantly improved the expression efficiency of mRNA in vivo . In addition, mRNAs can be efficiently produced by in vitro transcription at a relatively low cost, which increases its practicality. In theory, mRNA could be used as a vaccine by inducing immune responses against the protein it encodes. Mechanistically, the lipid nanoparticle-encapsulated mRNA can be efficiently taken up by dendritic cells, promoting expression of the antigen in these cells, and activating them by the adjuvant-like properties of the lipid nanoparticles. As the most important antigen-presenting cell in the immune system, dendritic cells digest the antigen into peptides, present them on class I and class II major histocompatibility complex (MHC) molecules on the cell surface, and induce specific immune responses by CD4 and CD8 T cells. The CD4-positive T cells are able to differentiate into different subsets and secrete cytokines to promote immune responses in the body. On the other hand, CD8-positive T cells develop into killer T cells during an infection to kill virus-infected cells. After vaccination, both CD4 and CD8 T cells eventually differentiate into memory T cells. In addition, B cells may also capture the antigen expressed by the mRNA and become activated. With the help from the CD4-positive T cells, these B cells can differentiate into memory B cells and long-lived plasma cells that produce high-affinity antibodies.

During the COVID-19 pandemic, mRNA vaccines have demonstrated striking efficacy in preventing infection. In the pre-clinical phase, mRNA-1273, the mRNA vaccine developed by Moderna, elicited strong immune responses in rhesus monkeys. High neutralizing antibody titers were detected in the serum and significant increases in T follicular helper cells expressing interleukin-21 were observed 4 weeks after the second vaccine dose. In phase III clinical trials including 30,420 volunteers, the effective rate of mRNA-1273 reached 94.1%. However, this vaccine had stringent storage requirements and required transportation at -20 °C. A thermostable mRNA vaccine, ARCoV, developed by scientists in China has also shown promising results. ARCoV elicited antibodies and cell-mediated immunity and also significantly lowered the viral load in animal experiments. Moreover, ARCov can be stored between The goal of introducing exogenous mRNA into the human body for intracellular protein expression is to turn the cells of the human body into 'factories' to produce the required proteins. This technology is not confined to COVID-19 vaccines, as researchers in many countries have designed and developed mRNA vaccines for other diseases such as the human immunodeficiency virus (HIV) and Zika virus. Nor was this technology confined to vaccines for pathogens, as mRNA vaccines against melanoma have been developed and are undergoing clinical trials. Moreover, mRNA-based technology can do more than producing vaccines. For example, by instructing the expression of correctly folded hemoglobin, mRNAs can be used to treat sickle-cell anemia. The mRNA vaccines have shone through the COVID-19 pandemic. Its success also serves as a vivid reminder that the return for investment on basic research may not be always instant, as 30 years have passed since the first proof of concept of the mRNA technology.

The authors declare that they do not have any conflicts of interest in this work.

Breakthrough Technologies 2021

His work has led to the discovery of the intercellular positive-feedback mechanism for antibody affinity maturation, the identification of memory Bcell precursors, the uncovering of the cell-biological basis for the sexual dimorphism of antibody responses, and the definition of the first brain-spleen neural pathway that regulates acquired immunity. He has published more than 50 papers in some of the most prestigious journals including Nature